Florence M J Potts, PT in Rifton, NY - Physical Therapist

Florence M J Potts, PT is a Physical Therapist based in Rifton, New York. Florence M J Potts is licensed to practice in New York (license number 015109) and her current practice location is 2032 Route 213 St, Rifton, New York. She can be reached at her office (for appointments etc.) via phone at (845) 658-8961.

NPI number for Florence M J Potts is 1558731976 and her current mailing address is 10 Hellbrook Ln, Ulster Park, New York. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1558731976.

Contact Information

	Florence M J Potts, PT
	2032 Route 213 St, Rifton, NY 12471-7700
	(845) 658-8961
	Not Available

Healthcare Provider's Profile

Full Name	Florence M J Potts
Gender	Female
Speciality	Physical Therapist
Location	2032 Route 213 St, Rifton, New York
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1558731976
Provider Enumeration Date: 09/28/2015
Last Update Date: 09/28/2015

Medical Identifiers

Medical identifiers for Florence M J Potts such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1558731976	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225100000X	Physical Therapist	015109 (New York)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Florence M J Potts is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Florence M J Potts, PT 10 Hellbrook Ln, Ulster Park, NY 12487-5209 Ph: (845) 658-7763	Florence M J Potts, PT 2032 Route 213 St, Rifton, NY 12471-7700 Ph: (845) 658-8961

News Archive

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

Surgical oncologist receives grant further explore tumor suppressor function of mutated gene

Darren Carpizo, MD, PhD, a surgical oncologist in the Liver Cancer and Bile Duct Cancer Care Program at the Cancer Institute of New Jersey, has been awarded a $200,000 grant from the Sidney Kimmel Foundation for Cancer Research to further explore the effects of a compound identified in his laboratory found to restore tumor suppressor function of a mutated gene in cancer cells.

GenSpera plans to initiate G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

Researchers reveal process by which pancreatic inflammation morphs into pancreatic cancer

Researchers at Mayo Clinic in Florida have revealed the process by which chronic inflammation of the pancreas, pancreatitis, morphs into pancreatic cancer. They say their findings point to ways to identify pancreatitis patients at risk of pancreatic cancer and to potential drug therapies that might reverse the process.

New drug helps children and young adults who have severe pain from sickle cell disease

Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease.

Florence M J Potts, PT - Physical Therapist in Rifton, NY